# Lila Sciences

> Source: https://aiwiki.ai/wiki/lila_sciences
> Updated: 2026-10-27
> Fact-checked: 2026-10-27
> Categories: AI Companies, AI for Science
> License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) - attribute to "AI Wiki (aiwiki.ai)"
> Cite as: AI Wiki. "Lila Sciences." aiwiki.ai, 27 Oct 2026. https://aiwiki.ai/wiki/lila_sciences
> From AI Wiki (https://aiwiki.ai), the free encyclopedia of artificial intelligence. Reuse freely with attribution.

**Lila Sciences** is a Cambridge, Massachusetts technology company that builds [artificial intelligence](https://aiwiki.ai/wiki/artificial_intelligence) systems coupled with automated laboratories, which it calls "AI Science Factories," in pursuit of what it brands "scientific [superintelligence](https://aiwiki.ai/wiki/superintelligence)" across chemistry, materials science, and the life sciences. Incubated inside the venture-creation firm Flagship Pioneering and led by chief executive Geoffrey von Maltzahn, the company emerged from stealth on March 10, 2025 with a $200 million seed round,[1][3] and by October 2025 had raised $550 million in total, after a Series A extension that the company told Reuters lifted its valuation to more than $1.3 billion.[11][12][20] In June 2026 Bloomberg News reported that Lila was in talks to raise about $2 billion in a Series B at a valuation of about $8.5 billion before the new money; as of late October 2026 the company had not announced a close.[21][22] Lila's stated approach closes a loop in which [AI agents](https://aiwiki.ai/wiki/ai_agents) propose hypotheses and experiments, robotic laboratories run them, and the physical results feed back to retrain the models. Through 2025 its headline scientific results were company claims without published supporting data.[12][15] In 2026 it began releasing more detail, including an arXiv preprint on AI-discovered catalysts for green hydrogen and preclinical mRNA and CAR-T results; it said the mRNA data had not been independently peer-reviewed.[23][24]

## Founding and Flagship Pioneering

Lila Sciences was created within the labs of Flagship Pioneering, the Cambridge firm founded by Noubar Afeyan that originated Moderna and [Generate:Biomedicines](https://aiwiki.ai/wiki/generate_biomedicines). Flagship and the company say Lila was founded in Flagship's labs in 2023;[1] Contrary Research's company profile lists a founding date of March 2022.[15] Co-founder Molly Gibson told The New York Times at launch that Lila resulted from the merger of two early AI company projects at Flagship, one focused on new materials and the other on biology, which were trying to solve similar problems and recruit the same people.[25] The venture stayed in stealth until it was publicly unveiled on March 10, 2025.[1] In its 2026 materials the company often styles its name in capitals as "LILA."[22]

Leadership combines Flagship operators with established academic scientists. Geoffrey von Maltzahn, a Flagship general partner who was previously the founding chief executive of Generate:Biomedicines, Tessera Therapeutics, Quotient Therapeutics and Indigo Ag, is co-founder and chief executive.[1][26] Noubar Afeyan was named co-founder and chairman at launch, and Molly Gibson, a Flagship origination partner, was named co-founder and president of future science.[1] Andrew Beam, a co-founder of Generate:Biomedicines and an associate professor of epidemiology at the Harvard T.H. Chan School of Public Health, is chief technology officer, and the Harvard geneticist George Church, known for foundational work in genome sequencing and synthetic biology, joined as chief scientist; both Beam and Church were named with the March 2025 launch.[1][27][25] The AI research group has been led in part by Kenneth Stanley, a machine-learning researcher who previously led the open-endedness team at [OpenAI](https://aiwiki.ai/wiki/openai) and who joined Lila as a senior vice president.[1][28] On the materials side, MIT professor Rafael Gómez-Bombarelli, named at launch as chief scientific officer of materials, is described by Lila as a co-founder and is chief scientific officer of physical sciences, and John Gregoire, formerly a research professor at Caltech, serves as chief autonomous science officer.[1][29][30] Christopher Fussell, a former U.S. Navy SEAL officer and co-author of the management book *Team of Teams*, was president of operations at launch.[1][31] Lila says it runs on a "Team of Teams" operating model of small, empowered teams with shared context.[32]

By October 2026, Lila's team page listed John Kim, a former chief client officer at [General Catalyst](https://aiwiki.ai/wiki/general_catalyst), as chair and president of corporate development, with von Maltzahn, Afeyan, Daniel de Faro Adamson and Alex Karnal as the other board members.[33][34] The same page listed Fussell as vice chair, Jawad Ahsan, a former chief financial officer of Axon, as chief operating officer and chief financial officer, and Julie Shah, head of MIT's Department of Aeronautics and Astronautics, as chief robotics officer.[33][31][35][36] Neither Church nor Gibson appeared on that page; Contrary Research's December 2025 profile already described Gibson as the former holder of her launch title.[15][33]

Sources differ on who counts as a founder. Flagship's launch release named von Maltzahn, Afeyan and Gibson as co-founders;[1] Lila's own biographies also describe Gómez-Bombarelli and Ben Kompa, its head of AI lab innovation, as co-founders;[29][37] and CNBC's 2026 Disruptor 50 profile listed ten founders: von Maltzahn, John Kim, Chris Fussell, Andy Beam, Gómez-Bombarelli, John Gregoire, Ben Kompa, Alex Sneider, Josh Waitzkin and Afeyan.[38]

| Person | Role at Lila (October 2026) | Background |
|--------|-----------------------------|------------|
| Geoffrey von Maltzahn | Co-founder, chief executive, board member | Flagship Pioneering general partner; founding CEO of Generate:Biomedicines, Tessera Therapeutics, Quotient Therapeutics and Indigo Ag[26] |
| John Kim | Chair; president of corporate development | Former chief client officer, General Catalyst[34] |
| Noubar Afeyan | Co-founder; board member (chairman at launch) | Founder and chief executive of Flagship Pioneering[1] |
| Chris Fussell | Vice chair (president of operations at launch) | Former president of McChrystal Group; former Navy SEAL officer[31] |
| Jawad Ahsan | Chief operating officer and chief financial officer | Former chief financial officer of Axon[35] |
| Andrew Beam | Chief technology officer | Co-founder of Generate:Biomedicines; associate professor, Harvard T.H. Chan School of Public Health[27] |
| Rafael Gómez-Bombarelli | Co-founder; chief scientific officer, physical sciences | MIT materials science faculty member since 2018[29] |
| John Gregoire | Chief autonomous science officer | Former Caltech research professor who directed its High-Throughput Materials program[30] |
| Julie Shah | Chief robotics officer | Head of MIT's Department of Aeronautics and Astronautics[36] |
| Kenneth Stanley | Senior vice president, open-endedness | Creator of the NEAT and novelty search algorithms; led OpenAI's open-endedness team[28] |
| Ben Kompa | Vice president, head of AI lab innovation | Named to MIT Technology Review's 35 Innovators Under 35 in 2026[22] |

## The "scientific superintelligence" vision

Lila frames its goal as building AI that can execute "every step of the scientific method," from generating a hypothesis to designing an experiment, running it physically, interpreting the data, and iterating.[8] The company calls the eventual product "scientific superintelligence," language deliberately echoing the artificial-general-intelligence ambitions of frontier AI labs but applied to laboratory discovery rather than general reasoning.

This branding should be read as the company's own marketing rather than a measured external assessment. "Superintelligence" here is an aspirational label for a system that the company says exceeds human and prior-AI benchmarks on specific tasks; it does not denote any independently verified general capability. Reporting on the broader field has stressed that no "ChatGPT moment" has yet arrived for autonomous scientific discovery, and that the hardest and most expensive steps in domains such as materials science are physical synthesis and testing, not computation.[14] As John Gregoire put it to MIT Technology Review, simulations are useful for framing what is worth testing, "but there's zero problems we can ever solve in the real world with simulation alone."[14]

Lila's technical pitch borrows the vocabulary of frontier AI labs. Its technology page says the company is training a scientific reasoning model on data generated by its own experiments, which it contrasts with internet data that it says has been exhausted. It presents the AI Science Factories as verifiers: in its account, [verifiable rewards](https://aiwiki.ai/wiki/rlvr) drove AI progress in math and coding, and running real experiments at scale can supply the same kind of reward signal for science.[39] The company calls itself "a new kind of frontier AI lab" that needs compute on the scale of leading language-model developers,[39] and says its strategy follows Rich Sutton's essay "The Bitter Lesson" in favoring one general platform that learns for itself over many narrow, domain-specific tools.[32] Reuters reported in October 2025 that the company believes future leadership in AI for science will depend on owning the largest automated lab, not just the biggest data center.[20]

## Autonomous AI Science Factories

Lila's central concept is the "AI Science Factory," which the company describes as a unified facility where [AI models](https://aiwiki.ai/wiki/model), custom software, and laboratory hardware "close the loop between reasoning and real-world verification."[8] In Lila's framing these are "scientific-method machines" that use [generative AI](https://aiwiki.ai/wiki/generative_ai) and [reinforcement learning](https://aiwiki.ai/wiki/reinforcement_learning) to propose experiments, then carry them out with robotics and automated instrumentation, capturing physical data that is fed back to improve the models.[8][1] The company speaks of producing "scientific tokens" by putting more instruments under [AI control](https://aiwiki.ai/wiki/ai_control), an analogy to the way [large language models](https://aiwiki.ai/wiki/large_language_model) consume text tokens.[11][39]

As of December 2025 the company operated a single AI Science Factory in development in Cambridge, with stated plans to expand to additional sites including San Francisco and London.[14][15] As of late October 2026 Lila's newsroom had announced no AI Science Factory outside Cambridge,[22] although a company-published profile that month described its open-endedness research team as working from a San Francisco office.[40] Reporting on the Cambridge facility describes AI-directed equipment such as sputtering systems producing thin-film alloy samples for materials work.[14] Lila has signed a 235,500-square-foot lease at Alewife Park in Cambridge, reported as the largest Greater Boston lab lease of the third quarter of 2025.[16] The developer, IQHQ, gave the size as 244,000 square feet when it announced the lease in October 2025, saying the space included both move-in-ready space and a new-construction laboratory building.[41] In August 2026 Lila described its newest AI Science Factory as a 270,000-square-foot purpose-built facility in Alewife that it said would be designed to run experimental cycles continuously, 24 hours a day.[24] Contrary Research noted in December 2025 that human scientists were still needed to supervise the machinery, which tempers the "fully autonomous" framing,[15] and in its September 2026 account of a catalyst campaign Lila said people still moved samples between instruments while it developed robots for fully autonomous operation.[42] Lila had about 100 employees earlier in 2025, according to the Boston Business Journal,[16] and one company-background report cited about 249 employees in December 2025.[15]

## Products and business model

Lila sells access to its platform through two offerings, both built on what it calls Lila Iris, its proprietary AI platform, together with its AI Science Factories. Catalyst gives a partner's own R&D teams access to Lila Iris, factory capacity and Lila scientists, which the company markets as "Lab-as-a-Service" that turns fixed lab capacity and capital spending into an on-demand resource.[43] Creation is an offering in which a partner brings a problem and Lila runs the discovery campaign, delivering validated assets such as structures, protocols and data packages; Lila also offers Creation campaigns to investors or strategic partners as a route to forming new companies around the resulting science and intellectual property.[44] Its website lists target industries including therapeutics, biotech, chemicals, advanced materials, energy and environment, oil and gas, and aerospace and defense.[45]

Lila has said it does not plan to carry products all the way to market itself. "We aren't going to bring molecules into clinical trials ourselves, or scale up new energy breakthroughs," von Maltzahn told Reuters in October 2025. "Those are going to be done by partners of Lila and startups that are on a Lila platform."[20] The company said that month that it was welcoming its first cohort of customers,[11] and Reuters reported interest from firms in energy, semiconductors and drug development, none of which Lila named.[20]

## Funding

Lila has raised capital quickly and from an unusually broad investor base spanning venture firms, sovereign wealth, pension funds, defense-linked funds, and a major chip maker. The seed round of $200 million was announced at launch in March 2025.[1][3] A Series A first close of $235 million, co-led by Braidwell and Collective Global, followed in September 2025,[8][9] and a $115 million extension in October 2025 brought the Series A to $350 million and cumulative funding to $550 million.[11][12] The company did not state a valuation in its own announcements, but the Boston Business Journal put it at about $1.23 billion after the September close,[16] and Lila told Reuters that the October extension lifted its valuation to more than $1.3 billion.[20]

| Round | Date (announced) | Amount | Reported valuation | Selected investors |
|-------|------------------|--------|--------------------|--------------------|
| Seed | March 10, 2025 | $200 million | Not disclosed | Flagship Pioneering, [General Catalyst](https://aiwiki.ai/wiki/general_catalyst), March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures, a subsidiary of the Abu Dhabi Investment Authority[1] |
| Series A (first close) | September 15, 2025 | $235 million | About $1.23 billion (Boston Business Journal)[16] | Co-led by Braidwell and Collective Global; also Alumni Ventures, Common Metal, NGS Super, the Mathers Foundation, and seed investors including Flagship Pioneering and General Catalyst[8] |
| Series A (extension) | October 2025 | $115 million | More than $1.3 billion (company, to Reuters)[20] | NVIDIA's NVentures, Analog Devices, IQT, Dauntless Ventures, Catalio Capital Management, Pennant Investors, members of Peter Diamandis' Abundance group[12] |
| Total | through October 2025 | $550 million | | Seed plus $350 million Series A[11] |
| Series B (reported talks) | June 3, 2026 (Bloomberg report) | About $2 billion (not announced) | About $8.5 billion before the new money (reported) | Reported anchors: CalPERS and NVentures[21] |

Coverage of the October 2025 extension led with the participation of [NVentures](https://aiwiki.ai/wiki/nvidia_nventures), NVIDIA's corporate venture arm.[12][13][20] The extension also brought in Analog Devices, which Lila said joined as part of Flagship's existing partnership with the chip maker, and IQT, the venture arm associated with the U.S. intelligence community; von Maltzahn wrote that the new investors brought "conviction in Lila's role in national security and U.S. resilience from materials discovery touching computing, energy, and infrastructure."[11]

### Reported Series B talks (2026)

On June 3, 2026, Bloomberg News reported, citing people familiar with the matter, that Lila was in talks to raise about $2 billion at an expected valuation of about $8.5 billion before the new money. According to those people, the Series B was anchored by the California Public Employees' Retirement System (CalPERS) and NVentures. Spokespeople for Lila and CalPERS declined to comment.[21] Some investor-research sites derive a post-money figure of about $10.5 billion by adding the reported $2 billion to the pre-money valuation, while noting that the terms were not final.[46]

As of October 27, 2026, Lila's newsroom carried no announcement of a Series B close,[22] and a Fast Company awards write-up honoring von Maltzahn, published on October 6, 2026, still described the company as having "recently raised a $350 million Series A."[47] A funding tracker noted in October 2026 that private-market data providers had listed a Series B as closed, but that Lila had not announced one and its terms remained unconfirmed.[48]

## Demonstrated results versus claims

At launch Lila publicized four categories of scientific results, alongside a claim that its language models had state-of-the-art reasoning on scientific problems and benchmarks.[1] As of late 2025 these remained company claims that had not been independently verified or published in peer-reviewed journals; Fierce Biotech noted in October 2025 that the company had not publicly released any data to support them.[12]

- Genetic medicine: in an April 2025 interview reported by Contrary Research, von Maltzahn said three non-experts in mRNA biology used the platform to find mRNA sequences more than three times as efficient as those used in the BioNTech or Moderna COVID-19 vaccines, measured by protein expression, in about four months.[15] Flagship's launch release described the result more generally as genetic medicine constructs that outperform commercially available therapeutics.[1] Independent verification was not available at the time.
- Antibodies and peptides: the company claims discovery and validation of hundreds of novel antibodies, peptides, and binders against a range of therapeutic targets.[1]
- Green hydrogen catalysts: Lila reports novel non-platinum-group-metal catalysts for green hydrogen production at a fraction of the cost of current commercial catalysts.[1] The New York Times reported at launch that two scientists working with the AI found a novel catalyst for green hydrogen in four months, after instructing it that the catalyst had to be abundant or easy to produce, unlike iridium.[25]
- Carbon capture materials: the company claims a new material for industrial-scale carbon capture with better capacity, thermal stability, and binding kinetics than leading products.[1]

Outside experts urge caution. Coverage of AI-driven materials science has noted that AI predictions frequently fail to translate into materials that can actually be synthesized, remain stable at real-world temperatures, and exhibit useful function, and that a separate effort by [Google DeepMind](https://aiwiki.ai/wiki/google_deepmind) to predict millions of new materials was later criticized for thin evidence of compounds meeting the bar of novelty, credibility, and utility at once.[14] Contrary Research's analysis noted that integrating robotic systems across diverse assay types in a single experimental pipeline remained unproven and that connectivity between laboratory instruments was a bottleneck.[15] At launch, outside scientists told The New York Times that they had not been able to evaluate Lila's work because it had operated in secret; the biochemist and Nobel laureate David Baker said, "More power to them, if they can do it," and added, "It seems beyond anything I'm familiar with in scientific discovery."[25] None of this disproves Lila's specific claims, but it underscores that the company's results await independent confirmation.

### Results disclosed in 2026

| Date | Area | What Lila reported | Form of disclosure |
|------|------|--------------------|--------------------|
| May 2026 | In vivo CAR-T | AI-designed anti-CD20 CAR mRNA in CD8-targeted lipid nanoparticles gave deeper, longer-lasting B-cell depletion than a benchmark in non-human primates | Abstract at the ASGCT 2026 annual meeting; company blog post (August 2026)[22][24] |
| August 2026 | mRNA stability | More than 950,000 mRNA sequences synthesized and tested; an erythropoietin mRNA matched a benchmark's day-2 protein output on day 15 | Company blog post; company says the data were not independently peer-reviewed[24] |
| September 2026 | Green hydrogen catalysts | 2,942 catalysts screened; iridium- and ruthenium-free palladium oxides, the best of which kept its overpotential below 0.5 V for 1,000 hours in acid | arXiv preprint[23]; company blog post[42] |

The most detailed disclosure is a preprint posted to arXiv on September 24, 2026 by Ken J. Jenewein and 21 co-authors, including Gregoire and Gómez-Bombarelli. It describes an AI-guided, human-supervised closed-loop platform, more than 90 percent automated, that combined combinatorial sputter synthesis, high-throughput screening, machine-learning composition-property models, adaptive multi-objective optimization and large-language-model reasoning to search for catalysts for the acidic oxygen evolution reaction. That reaction takes place at the anode of proton-exchange-membrane water electrolyzers, which rely almost entirely on iridium or ruthenium. The platform evaluated 2,942 catalysts across 53 material systems and 26 elements and surfaced iridium- and ruthenium-free complex oxides such as InMnPdOx and NiTaPdOx, which the authors say conventional design logic and off-the-shelf language models would not predict. In long-term tests in 1 M sulfuric acid at 10 mA cm-2, InMnPdOx kept its overpotential below 0.5 V over 1,000 hours of operation, while plain PdOx and NiTaPdOx crossed that threshold at about 200 and about 470 hours. In retrospective benchmarking, the authors report that their sequential learning agent advanced the activity-stability frontier faster than fixed-policy [Bayesian optimization](https://aiwiki.ai/wiki/bayesian_optimization) or in-context language-model selection.[23]

Lila's own account of the work says the pipeline screened catalysts about 17 times faster than a standard lab, at around 240 samples a week, cut human hands-on time per sample by more than 90 percent, and identified six palladium-based material families with a favorable balance of activity and stability. The company stressed that the result is a materials discovery rather than a commercial product and that durability testing in industrial-style form factors was continuing. "My former group at Caltech explored catalysts for this reaction for 12 years, and if a student had suggested trying this combination of elements, I would have advised them to try a more promising direction," Gregoire said in the post.[42]

In August 2026 Lila said its platform had designed, synthesized and tested more than 950,000 mRNA sequences in living cells, feeding each result back into a model that co-optimizes the 5' and 3' untranslated regions and the coding region. It reported that a Lila-designed mRNA for erythropoietin produced as much protein on day 15 as a benchmark mRNA did on day 2, and that its sequences showed longer half-lives than published benchmark sequences for five more payloads: Factor IX, IL-10, IL-22, eGFP and firefly luciferase. Applying the platform to in vivo CAR-T therapy, three Lila scientists with no prior CAR-T expertise designed anti-CD20 CAR mRNAs formulated in CD8-targeted lipid nanoparticles. In non-human primates, the company said, its constructs drove peripheral B cells to near zero by day 4 and held them there through day 14, while benchmark sequences rebounded past baseline by day 14, and the program took under six months at an estimated tenth of conventional R&D cost. Lila noted that the results are preclinical, that the mRNA data reflect internal testing that has not been independently peer-reviewed, and that comparisons were made against the best published sequences because proprietary industry formulations are not disclosed.[24]

## Partnerships and government programs

### NVIDIA

Besides investing through NVentures, NVIDIA has featured Lila in its life sciences announcements. When NVIDIA announced its BioNeMo Agent Toolkit on June 23, 2026, it named Lila Sciences, alongside Anthropic, Edison Scientific, OpenAI and Owkin, among the frontier labs and scientific agent builders integrating with [BioNeMo](https://aiwiki.ai/wiki/nvidia_bionemo).[49] In a companion post, Ben Kompa wrote that Lila post-trains reasoning models, including NVIDIA's open-weight [Nemotron](https://aiwiki.ai/wiki/nemotron) 3 models, on data from its AI Science Factories, and equips its agents with open BioNeMo models, proprietary Lila models, code-execution environments and simulations powered by NVIDIA ALCHEMI.[37] At [NVIDIA GTC Berlin 2026](https://aiwiki.ai/wiki/nvidia_gtc_berlin_2026) on October 21, 2026, a keynote video on the [NVIDIA Agent Toolkit](https://aiwiki.ai/wiki/nvidia_agent_toolkit) showed agents at Lila helping to design a potential B-cell lymphoma therapy, using virtual experiments to guide work in an automated lab.[50]

### DOE Genesis Mission

On July 22, 2026, Lila said three of its proposals had been selected for Phase I awards under the Lighthouse Challenges of the U.S. Department of Energy's [Genesis Mission](https://aiwiki.ai/wiki/genesis_mission), each with a national laboratory or university partner.[51]

| Project | Partners | Aim (as described by Lila) |
|---------|----------|----------------------------|
| AI-Enabled Electrochemical Refinery | Caltech, Lawrence Berkeley National Laboratory | An autonomous closed-loop electrocatalysis platform searching more than 10 billion combinations of feed gases, electrolytes and operating conditions to convert waste carbon into chemical products |
| Agentic AI-Driven Manufacturing of Polyethylene from Waste Carbon | Northwestern University, Argonne National Laboratory | A tandem route that converts captured carbon electrochemically into ethylene and then thermochemically into polyethylene |
| Autonomous Identification of Semiconductor Charge Transport Physics | National Laboratory of the Rockies | A multi-agent system working across more than 1,000 samples to derive testable equations for leakage current and breakdown in wide-band-gap semiconductors such as ZnO and AlN |

Lila said the Phase I teams would develop concepts with their partners over several months and could then apply for larger Phase II awards.[51]

## Recognition

| Date | Recognition |
|------|-------------|
| March 2026 | Named to Fast Company's list of the top 10 most innovative artificial intelligence companies of 2026, according to Lila[22] |
| May 19, 2026 | No. 25 on the 2026 CNBC Disruptor 50 list, the company's first appearance[38] |
| June 2026 | Named to Fast Company's 2026 World Changing Ideas list, according to Lila[22] |
| September 2026 | Ben Kompa named to MIT Technology Review's 35 Innovators Under 35, according to Lila[22] |
| October 6, 2026 | Von Maltzahn named one of Fast Company's 2026 Tech Visionaries of the Year (Next Big Things in Tech) "for automating execution of the entire scientific method"[47][22] |

## Significance

Lila Sciences sits at the center of a wave of well-funded startups applying [AI for science](https://aiwiki.ai/wiki/ai_for_science) and autonomous laboratories to discovery, alongside peers such as [Periodic Labs](https://aiwiki.ai/wiki/periodic_labs). Debarghya Das's "The Ultimate Neolab List" includes Lila; in the list's "Neolab?" column, which grades companies from "Clean" to "Not a neolab," Lila is rated "Mostly," with the note "Research-driven with giant raises, but wet-lab heavy rather than purely software."[52] The "scientific superintelligence" framing is ambitious and unproven. CNBC's 2026 Disruptor 50 profile acknowledged "questions around whether the hype surrounding Lila is running ahead of reality,"[38] and the 2026 disclosures, though more concrete than the launch claims, took the form of a preprint, a conference abstract and company blog posts rather than peer-reviewed journal papers. Whether Lila can convert large capital and a closed-loop lab architecture into reproducible, externally verified discoveries, rather than benchmark results announced in blog posts, is the central open question about the company as it moves from stealth to commercial deployment.

## See also

- [Periodic Labs](https://aiwiki.ai/wiki/periodic_labs)
- [CuspAI](https://aiwiki.ai/wiki/cuspai)
- [FutureHouse](https://aiwiki.ai/wiki/futurehouse)
- [AI for Science](https://aiwiki.ai/wiki/ai_for_science)
- [Genesis Mission](https://aiwiki.ai/wiki/genesis_mission)
- [Apoha](https://aiwiki.ai/wiki/apoha)
- [Harmonic (AI)](https://aiwiki.ai/wiki/harmonic_aristotle)
- [Math Inc and Gauss](https://aiwiki.ai/wiki/math_inc_gauss)
- [Jua](https://aiwiki.ai/wiki/jua_ept2)
- [WindBorne Systems](https://aiwiki.ai/wiki/windborne_systems)
- [List of neolabs](https://aiwiki.ai/wiki/list_of_neolabs)
- [Neolab](https://aiwiki.ai/wiki/neolab)

## References

1. Flagship Pioneering, "Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science," press release, March 10, 2025. https://www.flagshippioneering.com/news/press-release/flagship-pioneering-unveils-lila-sciences-to-build-superintelligence-in-science
2. PR Newswire, "Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science," March 10, 2025. https://www.prnewswire.com/news-releases/flagship-pioneering-unveils-lila-sciences-to-build-superintelligence-in-science-302397198.html
3. BioPharma Dive, "Flagship startup raises $200M in pursuit of 'scientific superintelligence,'" March 10, 2025. https://www.biopharmadive.com/news/lila-flagship-ai-superintelligence-startup-seed/742213/
4. Fierce Biotech, "With $200M in seed funding, Flagship-backed Lila Sciences touts ambitious AI vision," March 2025. https://www.fiercebiotech.com/biotech/new-flagship-backed-ai-firm-aims-build-scientific-superintelligence
5. SiliconANGLE, "Lila Sciences raises $200M to accelerate autonomous scientific research," March 10, 2025. https://siliconangle.com/2025/03/10/lila-sciences-raises-200m-accelerate-autonomous-scientific-research/
6. Pharmaphorum, "Scientific 'superintelligence' firm Lila launches with $200m," March 2025. https://pharmaphorum.com/news/scientific-superintelligence-firm-lila-launches-200m
7. C&EN (Chemical & Engineering News), "Boston AI start-up raises $200 million," March 2025. https://cen.acs.org/business/start-ups/Boston-AI-startraises-200-million/103/web/2025/03
8. Lila Sciences, "Welcoming New Partners in Our Mission to Build Scientific Superintelligence" (Series A first close, $235M), September 15, 2025. https://www.lila.ai/news/series-a-235-million
9. HPCwire, "Lila Sciences Nabs $235 Million to Build 'Scientific Superintelligence,'" September 15, 2025. https://www.hpcwire.com/2025/09/15/lila-sciences-nabs-235-million-to-build-scientific-superintelligence/
10. Fierce Biotech, "Flagship's Lila Sciences lands $235M to expand AI-powered autonomous research labs," September 2025. https://www.fiercebiotech.com/biotech/flagships-lila-sciences-lands-235m-expand-ai-powered-autonomous-research-labs
11. Lila Sciences, "Announcing Lila's $350M Series A and Incredible Partners on Our Mission," October 2025. https://www.lila.ai/news/announcing-the-close-of-our-series-a
12. Fierce Biotech, "Lila Sciences adds Nvidia-backed $115M to series A, bringing total haul to $350M," October 2025. https://www.fiercebiotech.com/biotech/lila-sciences-adds-115m-series-bringing-total-haul-350m-and-securing-backing-nvidia
13. HPCwire / insideHPC, "AI Science Factory Company Lila Announces Close of $350M Series A, with NVIDIA Backing," October 17, 2025. https://insidehpc.com/2025/10/ai-science-factory-company-lila-announces-close-of-350m-series-a-with-nvidia-backing-2/
14. MIT Technology Review, "AI materials discovery now needs to move into the real world," December 15, 2025. https://www.technologyreview.com/2025/12/15/1129210/ai-materials-science-discovery-startups-investment/
15. Contrary Research, "Report: Lila Sciences Business Breakdown & Founding Story," 2025. https://research.contrary.com/company/lila-sciences
16. Boston Real Estate Times, "Lila Sciences Signs 235,500-Square-Foot Cambridge Lab Lease," 2025. https://bostonrealestatetimes.com/lila-sciences-signs-235500-square-foot-cambridge-lab-lease-reports-bbj/
17. ARK Invest podcast, "How Lila Is Redefining Scientific Discovery With Geoffrey von Maltzahn," 2025. https://www.ark-invest.com/podcast/lila-redefining-scientific-discovery
18. March Capital, "Lila: Building Scientific Superintelligence," 2025. https://marchcp.com/lila-building-scientific-superintelligence/
19. LILA, "News," lila.ai, accessed August 2026. https://www.lila.ai/
20. Krystal Hu, Reuters (syndicated by Yahoo Finance), "Exclusive-AI lab Lila Sciences tops $1.3 billion valuation with new Nvidia backing," October 14, 2025. https://finance.yahoo.com/news/exclusive-ai-lab-lila-sciences-101645837.html
21. Michelle F. Davis and Rebecca Torrence, Bloomberg News (via Bloomberg Law), "Lila Sciences Said in Talks for Funds at $8.5 Billion Valuation," June 3, 2026. https://news.bloomberglaw.com/private-equity/lila-sciences-said-in-talks-for-funds-at-8-5-billion-valuation
22. Lila Sciences, "Research & News," lila.ai, accessed October 27, 2026. https://www.lila.ai/news
23. Ken J. Jenewein, Faezeh Habib Zadeh, Xiaoxiao Wang, et al. (22 authors, including John M. Gregoire and Rafael Gómez-Bombarelli), "AI-guided high-throughput discovery of iridium- and ruthenium-free palladium-oxide catalysts for durable acidic oxygen evolution," arXiv:2609.30133, submitted September 24, 2026. https://arxiv.org/abs/2609.30133
24. LILA Editorial Team, "From prompt to CAR-T: Inside Lila's RNA discovery engine," Lila Sciences, August 28, 2026. https://www.lila.ai/news/inside-lilas-rna-discovery-engine
25. Steve Lohr, The New York Times, "The Quest for A.I. 'Scientific Superintelligence'," March 10, 2025 (reprint linked from Lila's newsroom). https://livearticles.net/new-york-times/2574654.html
26. Lila Sciences, "Geoffrey von Maltzahn, PhD" (team biography), accessed October 27, 2026. https://www.lila.ai/team/geoffrey-von-maltzahn
27. Lila Sciences, "Andrew Beam, PhD" (team biography), accessed October 27, 2026. https://www.lila.ai/team/andrew-beam
28. Lila Sciences, "Kenneth Stanley, PhD" (team biography), accessed October 27, 2026. https://www.lila.ai/team/kenneth-stanley
29. Lila Sciences, "Rafael Gómez-Bombarelli, PhD" (team biography), accessed October 27, 2026. https://www.lila.ai/team/rafael-gomez-bombarelli
30. Lila Sciences, "John Gregoire, PhD" (team biography), accessed October 27, 2026. https://www.lila.ai/team/john-gregoire
31. Lila Sciences, "Chris Fussell" (team biography), accessed October 27, 2026. https://www.lila.ai/team/chris-fussell
32. Lila Sciences, "About," lila.ai, accessed October 27, 2026. https://www.lila.ai/about
33. Lila Sciences, "Team," lila.ai, accessed October 27, 2026. https://www.lila.ai/team
34. Lila Sciences, "John Kim" (team biography), accessed October 27, 2026. https://www.lila.ai/team/john-kim
35. Lila Sciences, "Jawad Ahsan" (team biography), accessed October 27, 2026. https://www.lila.ai/team/jawad-ahsan
36. Lila Sciences, "Julie Shah, PhD" (team biography), accessed October 27, 2026. https://www.lila.ai/team/julie-shah
37. Ben Kompa, Lila Sciences, "Building the agent-driven era of science with NVIDIA BioNeMo agent toolkit," June 22, 2026. https://www.lila.ai/news/building-the-agent-driven-era-of-science-with-nvidia-bionemo-agent-toolkit
38. Brad Quick, CNBC, "25. Lila Sciences" (2026 CNBC Disruptor 50), May 19, 2026. https://www.cnbc.com/2026/05/19/lila-sciences-cnbc-disruptor-50-ranking.html
39. Lila Sciences, "Technology," lila.ai, accessed October 27, 2026. https://www.lila.ai/tech
40. Matthew Hutson, Lila Sciences, "What's a science startup doing with an open-endedness team?," October 9, 2026. https://www.lila.ai/people-stories/whats-a-science-startup-doing-with-an-open-endedness-team
41. IQHQ, "IQHQ Partners with Lila Sciences for 244,000 SF Lease at Alewife Park," press release, October 16, 2025. https://iqhqreit.com/news/lila-sciences-at-alewifepark
42. Megan Scudellari, Lila Sciences, "How an AI-run lab cracked open green hydrogen's catalyst problem," September 25, 2026. https://www.lila.ai/news/how-an-ai-run-lab-cracked-open-green-hydrogens-catalyst-problem
43. Lila Sciences, "Catalyst," lila.ai, accessed October 27, 2026. https://www.lila.ai/lila-catalyst
44. Lila Sciences, "Creation," lila.ai, accessed October 27, 2026. https://www.lila.ai/lila-creation
45. Lila Sciences, "LILA | Scientific Superintelligence" (home page), accessed October 27, 2026. https://www.lila.ai/
46. Sacra, "Lila Sciences valuation, funding & news," accessed October 27, 2026. https://sacra.com/c/lila-sciences/
47. Ross Rubin, Fast Company, "These tech execs showed uncommon vision in 2026," October 6, 2026. https://www.fastcompany.com/91612657/tech-visionaries-year-next-big-things-in-tech-2026 (archived copy: https://web.archive.org/web/20261010123340/https://www.fastcompany.com/91612657/tech-visionaries-year-next-big-things-in-tech-2026)
48. Revenue Memo, "Lila Sciences funding: Every round, investor, and valuation (2026)," October 4, 2026. https://www.revenuememo.com/p/lila-sciences-funding
49. NVIDIA, "NVIDIA Announces BioNeMo Agent Toolkit: Tools for Agents to Accelerate Scientific Discovery," press release, June 23, 2026. https://investor.nvidia.com/news/press-release-details/2026/NVIDIA-Announces-BioNeMo-Agent-Toolkit--Tools-for-Agents-to-Accelerate-Scientific-Discovery/default.aspx
50. Brian Caulfield, NVIDIA Blog, "GTC Berlin 2026: Live Updates From NVIDIA CEO Jensen Huang's Keynote," October 21, 2026. https://blogs.nvidia.com/blog/gtc-berlin-2026-keynote/
51. LILA Editorial Team, "Powering American Science: LILA to join DOE's Genesis Mission," Lila Sciences, July 22, 2026. https://www.lila.ai/news/powering-american-science-lila-to-join-does-genesis-mission
52. Debarghya Das, "The Ultimate Neolab List," accessed October 27, 2026. https://debarghyadas.com/neolabs/